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Wylie Vale (1941–2012)Wylie W. Vale, Jr., professor and head of the Clayton Foundation
Laboratories for Peptide Biology at the Salk Institute for Biological
Studies, National Academy Member and world-renowned leader in
the ﬁeld of neuroendocrinology, passed away unexpectedly on Jan-
uary 3, 2012. He is survived by his wife Betty, his daughters Eliza-
beth and Susannah, his granddaughter Celeste, his father Wylie
Vale, Sr., and his brother Shannon.
Wylie was born and educated in Texas. He earned his Bachelor’s
degree in biology from Rice University in 1964 and his Ph.D. in
physiology and biochemistry from Baylor College of Medicine in
1968. Wylie trained with Roger Guillemin at Baylor and then
moved with the Guillemin group to the Salk Institute in 1970. Dur-
ing this early period of his scientiﬁc career, Wylie made major con-
tributions to discoveries relating to brain peptide hormones for
which Guillemin shared the Nobel Prize in 1977. In 1978, Wylie,
together with Jean Rivier and Marvin Brown, established a separate
department at the Salk Institute and entered into a high-stakeshttp://dx.doi.org/10.1016/j.febslet.2012.05.031race with the Guillemin lab to be the ﬁrst to isolate and character-
ize corticotropin-releasing factor (CRF), the brain hormone that ini-
tiates the body’s stress response. In 1981, following a heroic effort,
the Vale team prevailed and presented the primary structure of the
41 amino acid CRF peptide in Science. Subsequently, Wylie and his
team led in the discovery of three CRF-related factors called uro-
cortins, two CRF receptors and a CRF binding protein. Wylie and
his group went onto make major contributions to understanding
the signaling mechanisms and physiology of these molecules
resulting in a body of work that has profound relevance to human
health since CRF and related peptides regulate anxiety, depression,
cardiac function, anorexia, diabetes and drug abuse. The Vale team
also discovered growth hormone releasing factor (GRF) in 1982, a
brain peptide that controls the body’s growth. Overall, he led in
the discovery of over a dozen neuropeptides and their signaling
mechanisms.
Wylie and his research team also made multiple seminal contri-
butions to the TGF-b ﬁeld. In 1985, Wylie’s group was one of sev-
eral other groups to isolate inhibin, an unusual a–b heterodimer
and potent inhibitor of FSH secretion from pituitary gonadotropes.
A year later, he co-discovered activin, a b–b homodimer, and pro-
posed that activin plays an autocrine/paracrine role in regulating
pituitary FSH release and that its actions could be opposed by inhi-
bin originating from the gonads. In addition to characterizing its
pituitary roles, Wylie and his collaborators were also quick to pro-
vide evidence for a much broader role for activin, showing that it is
widely distributed throughout the body with pleiotropic effects on
cell secretion, proliferation, differentiation and survival.
In 1991, Wylie and postdoctoral fellow Lawrence Mathews used
an expression cloning approach to clone ActRII, a transmembrane
receptor serine threonine kinase and the ﬁrst receptor for a mem-
ber of the TGF-b superfamily to be identiﬁed as such. This discov-
ery led to the subsequent cloning by Wylie’s group and others of a
dozen related serine threonine kinase receptors that are now
known to mediate all signaling functions of TGF-b superfamily
members. These receptors are ubiquitous and play critical roles
in wide ranging aspects of cellular behavior under normal and
pathological conditions. Wylie and his colleagues identiﬁed, along
with others, additional TGF-b superfamily receptors as well as sev-
eral signaling molecules downstream of these receptors, which
were important advances in the delineation of this pathway.
Wylie recognized that an understanding of structure was essen-
tial for understanding mechanism, and he collaborated with Sen-
yon Choe’s group at the Salk Institute to determine the X-ray
crystal structure of the ActRII activin receptor extracellular domain
(ECD). Signiﬁcantly, this was the ﬁrst receptor of this class for
which the structure of the extracellular ligand-binding domain
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three ﬁnger cardiotoxin fold later found to be prototypical for
ECD’s of receptors of the TGF-b superfamily. This structure allowed
Wylie and colleagues to deﬁne the functional binding site for acti-
vin-A and inhibin-A on ActRII by mutagenesis analysis of the Ac-
tRII-ECD. These results were extended and conﬁrmed when the
Vale and Choe groups solved the crystal structure of the activin-re-
lated factor BMP7 bound to the ActRII-ECD. Wylie’s group was also
the ﬁrst to identify critical ECD binding residues for activin on its
type I receptor ALK4.
In addition to his work on activin signaling mechanisms and
physiology, Wylie also contributed greatly to our understanding
of activin counter-regulation. For many years, determining the
molecular mechanism of inhibin action represented the holy grail
in the activin and inhibin ﬁeld. Wylie led another expression clon-
ing effort and identiﬁed betaglycan (type III TGF-b receptor) as an
inhibin binding protein. Vale and colleagues showed that betagly-
can forms a high-afﬁnity complex with inhibin and ActRII and pro-
posed that this complex blocks activin signaling by removing
ActRII from the available pool of signaling receptors. Subsequent
work from the Vale group and others has validated betaglycan as
a mediator of inhibin action and shown that inhibin, through its
ability to sequester type II receptors, can also block BMP signaling.
In addition to this work on inhibin, Wylie, together with Wolfgang
Fischer and colleagues, generated mutant activins with activity as
potent activin type II receptor antagonists. He also collaborated
with Louise Bilezikjian to characterize follistatin regulation and
function as an activin antagonist in the pituitary and Peter Gray
to discover a role for Cripto as an activin and TGF-b antagonist with
implications for stem cell function and tumorigenesis.
Although he focused on basic research, Wylie wanted to see his
discoveries developed into useful therapies. To this end, he co-
founded two biotech companies, Neurocrine Biosciences, whichhas focused on developing drugs relating to CRF and its receptors,
and Acceleron Pharma, which has utilized the activin type II recep-
tor ECD’s to develop compounds for the treatment of anemia, mus-
cle and skeletal disorders and cancer.
Wylie loved novelty and discovery and his passion and enthusi-
asm for science were contagious. As a mentor, he fostered indepen-
dence but was quick to provide encouragement and the necessary
guidance. Wylie had an immensely productive career and his
prowess as an investigator coupled with his popularity and respect
among his colleagues led to countless successful collaborations.
Amazingly, he authored and co-authored nearly 900 publications.
Perhaps this is the best evidence of the number of scientists he
inﬂuenced. He will truly be missed.
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